Phaseline

Targets › GRIN3B

GRIN3B (Glutamate receptor ionotropic, NMDA 3B): drug programs, companies and trials

47 programs from 46 companies in 96 trials: 33 Phase 2, 27 Phase 4, 19 Phase 3, 17 Phase 1; Psychiatry, Neurology, Oncology; next expected readout Nov 2026.

Component of a non-conventional N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with low calcium permeability and low voltage-dependent block by Mg(2+) (By similarity). Forms glutamatergic receptor complexes with GluN1 and GluN2 subunits which are activated by glycine binding to the GluN1 and GluN3 subunits and L-glutamate binding to GluN2 subunits (By…. (UniProt, O60391)

Open in Phaseline: the race on GRIN3B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Stanford UniversityKetamine Hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Chronic Pain; Obsessive-Compulsive Disorder; Epilepsy; Psychiatric DisorderNov 2026
University of Puerto RicoEsketamine Hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Treatment-resistant Depression (TRD)Dec 2026
National Institute on Alcohol Abuse and Alcoholism (NIAAA)Acamprosate calcium
Glutamate [NMDA] receptor antagonist; GABA-A receptor; anion channel positive modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Alcohol Use DisorderDec 2026
University of OklahomaKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Laceration of Skin; HemorrhoidsJan 2027
Ain Shams UniversityKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Intraoperative Awareness; Perioperative Analgesia; Sedation and Analgesia; Inhalation AnesthesiaFeb 2027
Margaux M. Salas, PhDKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Neuropathic PainMay 2027
Universidad de AntioquiaKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Pain, PostoperativeJun 2027
Icahn School of Medicine at Mount SinaiKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Major Depressive Disorder; DepressionAug 2027
Massachusetts General HospitalKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Major Depressive Disorder; DepressionJun 2030
University Health Network, TorontoKetamine hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Chronic Daily Headache; Major Depressive DisorderFeb 2027
Nantes University HospitalKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Rapid Sequence InductionApr 2027
Canadian Cancer Trials GroupMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Brain MetastasesJun 2027
State University of New York at BuffaloKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Distal Radius Fracture ReductionAug 2027
Children's Oncology GroupMemantine Hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Central Nervous System CarcinomaSep 2027
Assistance Publique - Hôpitaux de ParisKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Major Depressive Episode; Limb InjuryFeb 2028
Dr. Inge WinterEsketamine hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Major Depressive DisorderJun 2028
Johnson & Johnson (Janssen)Esketamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Depressive Disorder, Treatment-Resistant; Depressive Disorder, Major; Sleep Wake Disorders; Prenatal Depression …Dec 2028
Yale Universityketamine hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Depression; Parkinson's Disease; Posttraumatic Stress Disorder; Depressive Disorder, MajorJan 2029
Tata Memorial CentreMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Neurocognitive DysfunctionJan 2031
NRG OncologyMemantine Hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Metastatic Lung Small Cell CarcinomaJul 2031
Reinier de Graaf GroepEsketamine hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Endometriosis–
NYU Langone HealthKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Chronic Postsurgical Pain–
Dr. med. Marcus HerdenerKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Cocaine Use Disorder; Alcohol Abuse/DependenceDec 2026
University of VirginiaMemantine Hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Alzheimer DiseaseDec 2026
The University of Texas Health Science Center at San AntonioKetamine Hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Suicide; Suicidal IdeationDec 2026
National Institute of Mental Health (NIMH)Ketamine Hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Healthy Volunteers; Healthy Volunteer; DepressionJan 2027
Case Comprehensive Cancer CenterMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Brain MetastasesMay 2027
University of ChicagoMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Skin-PickingJun 2027
Shanghai Mental Health CenterMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Obsessive-Compulsive DisorderJun 2027
Christian Hassageresketamine hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Out-of-hospital Cardiac Arrest (OHCA)Sep 2027
University of PennsylvaniaAmantadine
Glutamate [NMDA] receptor antagonist; Matrix protein 2 inhibitor
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Stroke, IschemicDec 2027
Medical College of WisconsinMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Brain MetastasesMay 2028
Inova Health Care ServicesMemantine Hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Hepatocellular CarcinomaJul 2028
University of Maryland, BaltimoreKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Opioid Use DisorderAug 2028
VA Office of Research and DevelopmentKetamine hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Chronic Low Back Pain; Parkinson's DiseaseDec 2028
UNC Lineberger Comprehensive Cancer CenterMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Breast CancerJun 2029
Samer GawriehAcamprosate
Glutamate [NMDA] receptor antagonist; GABA-A receptor; anion channel positive modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Alcohol-associated HepatitisDec 2029
The University of Texas Health Science Center at San AntonioMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Brain TumorJul 2030
University of EdinburghAmantadine
Glutamate [NMDA] receptor antagonist; Matrix protein 2 inhibitor
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Motor Neuron Disease, Amyotrophic Lateral SclerosisDec 2030
SHINKEI TherapeuticsAmantadine Hydrochloride (MR-301)
Glutamate [NMDA] receptor antagonist; Matrix protein 2 inhibitor
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Traumatic Brain Injury–
Sohag UniversityKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Generalized Convulsive Status Epilepticus; Convulsive Status EPILEPTICUS–
Children's Hospital Medical Center, CincinnatiMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Fragile X Syndrome–
University of ZurichMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 1GlioblastomaDec 2026
Bjorn H. EbdrupMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 1PsychosisDec 2026
Jeffrey MillerMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 1Major Depressive Disorder (MDD)Jun 2027
National Institute of Neurological Disorders and Stroke (NINDS)Acamprosate calcium
Glutamate [NMDA] receptor antagonist; GABA-A receptor; anion channel positive modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 1Amyotrophic Lateral SclerosisSep 2027
University of UtahKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 1Opioid-use Disorder; PainDec 2027

Conditions

Major Depressive Disorder (7) Depression (4) Brain Metastases (3) Hepatocellular Carcinoma (2) Opioid Use Disorder (2) Parkinson's Disease (2) Depressive Disorder, Major (2) Pain, Postoperative (2) Rapid Sequence Induction (2) Neuropathic Pain (2) Scoliosis Correction (2) Obsessive-Compulsive Disorder (2)

Modalities

small molecule (43), mixed (2), protein or peptide (1)

Companies

The University of Texas Health Science Center at San Antonio (2) Reinier de Graaf Groep (1) Christian Hassager (1) Massachusetts General Hospital (1) Samer Gawrieh (1) Children's Oncology Group (1) Tata Memorial Centre (1) University of Zurich (1) Dr. med. Marcus Herdener (1) Medical College of Wisconsin (1) Ain Shams University (1) National Institute of Mental Health (NIMH) (1) SHINKEI Therapeutics (1) University of Oklahoma (1) Assistance Publique - Hôpitaux de Paris (1) Icahn School of Medicine at Mount Sinai (1) University of Puerto Rico (1) Inova Health Care Services (1) University of Maryland, Baltimore (1) University Health Network, Toronto (1)

Related targets

GRIN1 (47) GRIN2A (47) GRIN2B (47) GRIN2D (47)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.